Pharmafile Logo
Pharmafocus logo
Advanced Search

Merck

Showing 15 posts of 360 posts found.

FDA committee recommends MSD’s c. diff prevention drug

June 10, 2016
Medical Communications, Research and Development, Sales and Marketing FDA, MSD, Merck, bezlotoxumab, committee, zinplava

The US Food and Drug Administration’s (FDA) antimicrobial drugs advisory committee has voted by 10 to 5, with one abstention, …

News
merckwindow

MSD to collaborate with Fujifilm Diosynth on new microbial biologics facility

June 7, 2016
Manufacturing and Production, Research and Development MSD, Merck, fujifilm diosynth

MSD, known as Merck in the US and Canada, has entered into a collaboration with Fujifilm Diosynth Biotechnologies to invest …

News
gavel

Judge reverses verdict in MSD/Gilead hepatitis C dispute

June 7, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Gilead, MSD, Merck, dispute, patent, reversal, sovaldi

A US district judge has reversed a previous court decision which favoured MSD, called Merck in the US, over Gilead …

News
test_results

Pivotal avelumab data in Merkel cell carcinoma presented at ASCO

June 6, 2016
Manufacturing and Production, Research and Development ASCO, Merck, Pfizer, avelumab, merkel cell carcinoma

New data presented at the American Society of Clinical Oncology’s annual general meeting has shown that avelumab, an investigational anti-PD-L1 …

News

Trial data shows promise for Lilly/MSD combo regimen in lung cancer

June 6, 2016
Research and Development, Sales and Marketing MSD, Merck, collaboration, immuno-oncology, lilly, lung cancer, non-small cell, parternship

Eli Lilly (NYSE: LLY) has presented data at the American Society of Clinical Oncology (ASCO) annual congress showcasing its collaborations …

News
stocks1

Weekly Movers: Valeant, Anacor, Regeneron…

May 23, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Acorda, Aduro Biotech, Anacor Pharma, Financial, MacroGenics, Merck, Regeneron Pharma, Valeant Pharma

The earnings season came to a close with Germany’s Merck doubling its first-quarter profits. For the week, drug trials, analyst …

Feature

Germany’s Merck Q1 profits double boosted by Sigma-Aldrich deal

May 19, 2016
Business Services, Sales and Marketing Financial, Merck, Q1, Sigma-Aldrich, deal, earnings, results

Germany’s Merck on Thursday said first-quarter net profit more than doubled helped by the integration of US laboratory equipment maker …

News
sample

Merck’s colorectal cancer drug meets primary endpoint in Phase III study

April 25, 2016
Research and Development, Sales and Marketing Erbitux, Merck, Serono, cancer drugs, colorectal cancer, increased survival, oncology, phase 3, phase III

Merck (FWB: MRK) has announced that its Phase III clinical trial of Erbitux, in combination with Folfox, met its primary …

News
keytruda1

MSD receives fourth Breakthrough Therapy Designation for Keytruda

April 19, 2016
Manufacturing and Production, Research and Development Breakthrough Therapy Designation, FDA, Hodgkin lymphoma, MSD, Merck, breakthrough designation, breakthrough therapy, keytruda

MSD (NYSE: MRK) has announced that the US Food and Drug Administration has granted Breakthrough Therapy Designation to Keytruda (pembrolizumab) …

News
mr058666-web

Merck appoints Maya Martinez-Davis as global head of oncology

April 14, 2016
Medical Communications Merck, maya martinez-davis, oncology

Merck has announced the appointment of Maya Martinez-Davis as the new global head of oncology at the German-based company. In …

Appointment
msd

FDA accepts biologics license application for MSD’s allergy immunotherapy drug

April 13, 2016
Research and Development, Sales and Marketing MSD, Merck, allergy, dust mite, house, immunotherapy, mk-8237

MSD (NYSE: MRK) has announced that the US Food and Drug Administration has accepted for review the biologics license application …

News
trials

Phase III trial initiated in Merck and Pfizer partnership for renal cell carcinoma drug

April 6, 2016
Research and Development Merck, Pfizer, avelumab, carcinoma, inlyta, javelin, partnership, phase III, renal

The first patient has been treated in the Phase III clinical trial, which sees Merck (ETR: MRK) and Pfizer (NYSE: …

News
mr058666-web

Merck receives CE Mark approval for new liquid biopsy test for colorectal cancer

April 6, 2016
Medical Communications, Research and Development, Sales and Marketing CE Mark, Merck, biomarker, biopsy, colorectal cancer, liquid biopsy, ras, sysmex inostics

Merck (ETR: MRK) has announced that their new liquid biopsy RAS biomarker test for metastatic colorectal cancer, developed in collaboration …

News
clinical_trial-web

OncoMed initiates Phase Ib immuno-oncology combination clinical trial

March 18, 2016
Medical Communications, Research and Development Merck, OncoMed, clinical trial, demcizumab, immuno-oncology, immuno-oncology combination, pembrolizumab, phase ib

OncoMed (NASDAQ: OMED) has announced the beginning of its Phase Ib clinical trial to investigate if the combination of demcizumab …

News
karl_ludwig_kley

Merck chief executive Karl-Ludwig Kley to step down in April

March 9, 2016
Medical Communications, Research and Development Denreon, Karl-Ludwig Kley, Merck, karl ludwig kley

 It has been announced that Karl-Ludwig Kley, chief executive officer at Merck, will step down from his position at the …

Appointment

Latest content

Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China

June 28, 2024

AbbVie’s Tepkinly gains positive CHMP opinion for follicular lymphoma treatment

June 28, 2024

IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer

June 27, 2024

Immunotherapy created at Roswell Park Comprehensive Cancer Center given expanded ODD by FDA

June 27, 2024

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024